Search Results

The Dideco D732 MICRO 27 Ph.I.S.I.O. with 27 micron screen with phosphoryIcholine coating is recommended for use in the arterial line of the extracorporeal circuit during any procedure that requires cardiopulmonary bypass. The fitter is used to trap and remove gaseous emboli as well as particulate debris that maybe introduced through the arterial line. The device should not be used longer than 6 hours. Contact with blood for longer periods is not advised.

The D732 MICRO 27 Ph.I.S.I.O. is sterile, non-pyrogenic disposable filter for use in the arterial line of the cardiopulmonary bypass circuit with the flow rate not exceeding 7.0 liters/minute. The D732 MICRO 27 Ph.I.S.I.O. is an Adult Arterial Filter with 27 micron filter screen designed to remove potentially harmful gaseous emboli, aggregated blood constituents, and particulate debris greater than 27 microns from the arterial line perfusate. The D732 MICRO 27 Ph.I.S.I.O. is a modified version of the currently marketed D732 MICRO 20. The modification consists of coating all blood contact surfaces with phosphoryicholine additive that improves the blood compatibility of the substrate materials and change of the pleated polyester filter screen pore size from 20 to 27 micron. Other than this change the D 732 MICRO 27 Ph.I.S.I.O. and the D 732 MICRO 20 are identical in design, materials, and manufacturing processes.

This document is a 510(k) summary for the D732 MICRO 27 Ph.I.S.I.O. adult arterial filter. It focuses on demonstrating substantial equivalence to a predicate device and outlining non-clinical and in vitro test results rather than a detailed study design with acceptance criteria tables.

However, based on the provided text, I can extract the following information about the acceptance criteria and the study that proves the device meets them:

1. A table of acceptance criteria and the reported device performance:

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):

• Sample Size for Test Set: Not explicitly stated. The document mentions "a complete battery of tests" and that "all tests were performed on sterilized aged devices comparing the D732 MICRO 27 Ph.I.S.I.O. vs. the D732 MICRO 20 non aged unmodified device." This implies multiple units were tested for each characteristic but the exact number is not provided.
• Data Provenance: Not specified. The performing laboratories or country of origin for the data are not mentioned. The document is submitted by an Italian company, but this doesn't confirm where the testing occurred.
• Retrospective or Prospective: These were likely prospective laboratory tests conducted specifically for this 510(k) submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience):

• This information is not applicable as the described tests are in vitro and biocompatibility tests, not studies requiring expert interpretation of clinical data or images. The "ground truth" is established by adherence to recognized standards and objective laboratory measurements.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

• This information is not applicable for these types of laboratory performance and biocompatibility studies. Adjudication methods are typically used in clinical trials or studies involving human expert assessment where there might be disagreements in interpretation.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• This information is not applicable. The device is an arterial filter, not an AI-powered diagnostic or assistive tool for human readers. No MRMC study was conducted.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• This information is not applicable. The device is a physical medical device, an arterial filter, not an algorithm.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

• The "ground truth" for the performance characteristics and biocompatibility of the device is based on International Standards (ISO 10993-1:1995 and AAMI Standard for filtration efficiency) and FDA Guidance documents ("Guidance for Cardiopulmonary Bypass Arterial Line Blood Filter 510(k) Submission" Final Guidance for Industry, dated November 29, 2000). The product's performance is compared against predefined specifications derived from these standards and guidance.

8. The sample size for the training set:

• This information is not applicable. The device is a physical medical device that undergoes performance and biocompatibility testing, not an AI or machine learning algorithm that requires a training set.

9. How the ground truth for the training set was established:

• This information is not applicable for the reasons stated in point 8.

Ask a specific question about this device

The Dideco D731 MICRO 20 Ph.I.S.I.O., with 20 micron screen with phosphorylcholine coating and the Dideco D733 MICRO 40 Ph.I.S.I.O., with 40 micron screen with phosphorylcholine coating are recommended for use in the arterial line of the extracorporeal circuit during any procedure that requires cardiopulmonary bypass. The filters are used to trap and remove gaseous emboli as well as particulate debris that maybe introduced through the arterial line. The device should not be used longer than 6 hours. Contact with blood for longer periods is not advised.

The D731 MICRO 20 Ph.I.S.I.O. and D733 MICRO 40 Ph.I.S.I.O. are sterile, non-pyrogenic disposable filters for use in the arterial line of the cardiopulmonary bypass circuit with the flow rate not exceeding 5.0 liters/minute. The D731 MICRO 20 Ph.I.S.I.O. and D733 MICRO 40 Ph.I.S.I.O. are Pediatric Arterial Filters with 20 and 40 micron filter screens designed to remove potentially harmful gaseous emboli, aggregated blood constituents, and particulate debris greater than 20 and 40 microns respectively from the arterial line perfusate. The D731 MICRO 20 Ph.J.S.I.O. and D733 MICRO 40 Ph.I.S.I.O. are a modified version of the currently marketed D731/D733 MICRO. The modification consists of coating all blood contact surfaces with phosphoryIcholine additive that improves the blood compatibility of the substrate materials. Other than this change the D 731/D733 MICRÓ Ph.I.S.I.O. and the D 731/D733 MICRO are identical in design, materials, and manufacturing processes.

The provided document is a 510(k) summary for a medical device modification, specifically for the D731 MICRO 20 Ph.I.S.I.O. and D733 MICRO 40 Ph.I.S.I.O. Pediatric Arterial Filters. This document focuses on demonstrating substantial equivalence to a predicate device rather than presenting a study where a device's performance is measured against specific acceptance criteria.

Therefore, the requested information categories regarding acceptance criteria, study design, sample sizes, ground truth establishment, expert qualifications, and comparative effectiveness studies are largely not applicable or explicitly detailed in this type of regulatory submission.

Here's an breakdown of what can be extracted or inferred from the provided text, and what cannot:

1. Table of acceptance criteria and reported device performance:

This document does not provide a table of acceptance criteria with numerical targets. Instead, it states that "The results of the testing met established specifications" for various tests. The performance is reported in terms of "comparable" or "substantially equivalent" to the unmodified predicate devices.

2. Sample size used for the test set and the data provenance:

• Sample size: Not explicitly stated as a numerical count of devices tested. The document mentions "A complete battery of tests" and "Tests were performed on sterilized aged devices comparing the D731 MICRO 20 Ph.I.S.I.O. vs. the D733 non aged unmodified device and D731 MICRO 40 Ph.I.S.I.O vs. D733 non aged unmodified device". The testing for biocompatibility was performed on the D733 MICRO Ph.I.S.I.O. (accelerated aging) and the data was considered applicable to D731 MICRO 20 Ph.I.S.I.O. There's no specific "test set" size quantified for each parameter.
• Data provenance: Not explicitly stated (e.g., country of origin, retrospective/prospective). This is a regulatory submission, so the data would have been generated internally by the manufacturer or by a contracted lab. It's laboratory-based testing, not clinical data from patients.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• Not applicable. The "ground truth" in this context is based on objective, standardized laboratory measurements against established specifications for device performance, not expert human interpretation (like in imaging studies).

4. Adjudication method for the test set:

• Not applicable. See point 3. Testing involves objective measurements, not human adjudication.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• Not applicable. This document describes a medical device (arterial filter) for mechanical function and biocompatibility, not an AI-powered diagnostic or interpretive tool. Therefore, MRMC studies and "human readers" are irrelevant.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

• Not applicable. See point 5. This is not an algorithm.

7. The type of ground truth used:

• Objective Laboratory Specifications and Predicate Device Performance: The "ground truth" for the test results is adherence to pre-established scientific/engineering specifications (e.g., ISO 10993 standards for biocompatibility) and performance comparability to the unmodified predicate devices.

8. The sample size for the training set:

• Not applicable. This is not a machine learning model, so there is no "training set."

9. How the ground truth for the training set was established:

• Not applicable. See point 8.

Ask a specific question about this device

The ECC.O is intended for use in patients who undergo surgical procedures requiring extracorporeal gas exchange support and blood temperature control with a maximum blood flow rate of 5 liters/minute. ECC.O must not be used longer than 6 hours. Contact with blood for longer periods is inadvisable. ECC.O is intended for use with the Stockert Centrifugal Pump Console.

The ECC.O System with Integrated Venous Air Removal Device, Centrifugal Blood Pump, Pump Bracket. Hollow Fiber Oxygenator and Heat Exchanger is an extracorporeal hemodynamic and gas exchange support system for extracorporeal perfusion. ECC.O consists of a high efficiency, microporous, hollow fiber membrane oxygenator integrated with a heat exchanger connected to a venous air removal device (defoamer) (Ideal Mimesys' Venous Air Removal Device, K032040), a centrifugal pump (Ideal Mimesys' Centrifugal Pump, K032040) and a pump bracket.

The acceptance criteria and the study proving the device meets them are described below:

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly list a table of acceptance criteria with numerical targets. Instead, it refers to compliance with established specifications and guidance documents. The reported device performance is presented as meeting these specifications.

2. Sample Size Used for the Test Set and Data Provenance:

The document does not explicitly state a sample size for the test set in terms of number of devices or data points used for each specific in vitro test. It generally states that "Applicable tests were carried out" and "In vitro testing was carried out."

Regarding data provenance:

• Country of Origin: Not specified for the test data, but the submitter (Dideco S.r.l.) is based in Mirandola (MO), Italy.
• Retrospective or Prospective: The testing described appears to be prospective as it involves new in vitro tests on the ECC.O system, as well as comparative testing with the D 905 EOS assembled with predicate devices. The biocompatibility data from predicate devices are used as a reference, which could be considered retrospective in a way, as it leverages prior testing. The ECC.O devices were "accelerated aged to an equivalent of three years real time aging" for some tests.

3. Number of Experts Used to Establish Ground Truth and Qualifications:

Not applicable in this context. This submission describes non-clinical (in vitro) testing and substantial equivalence to predicate devices, not studies involving human interpretation or clinical outcomes where expert ground truth would be established.

4. Adjudication Method for the Test Set:

Not applicable, as this is a non-clinical evaluation based on laboratory testing against established specifications and comparative performance with predicate devices.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No, an MRMC comparative effectiveness study was not conducted or described in this document. This submission is for a medical device (extracorporeal circulation system), not an AI-powered diagnostic or imaging interpretation tool where such studies would be relevant.

6. Standalone Performance:

Yes, a standalone performance evaluation was conducted in the sense that the ECC.O system was subjected to various in vitro tests to assess its algorithm-only equivalent performance (i.e., the device's functional and safety performance without human intervention during the test itself). The results were then compared to established specifications and the performance of predicate devices.

7. Type of Ground Truth Used:

The "ground truth" for this device evaluation is primarily based on:

• Established Specifications: Predetermined performance targets and safety limits derived from regulatory standards (e.g., ISO 10993-1, ISO 7199), FDA guidance documents (e.g., for Cardiopulmonary Bypass Oxygenators, Blood Extracorporeal Blood Circuit Defoamers), and internal validated engineering and design specifications.
• Predicate Device Performance: The functional performance of the predicate devices (D 905 EOS, Ideal Mimesys' Centrifugal Pump, Ideal Mimesys' Venous Air Removal Device) served as the benchmark for demonstrating substantial equivalence.

8. Sample Size for the Training Set:

Not applicable. This device is not an AI/ML model that requires a "training set." The testing described is for a physical medical device.

9. How the Ground Truth for the Training Set Was Established:

Not applicable, as there is no "training set" for this type of device.

Ask a specific question about this device

The Performa Adult Hollow Fiber Membrane Oxygenator is intended for use in adult surgical procedures requiring extracorporeal gas exchange support and blood temperature control for periods of up to 6 hours.

The Performa Adult Hollow Fiber Oxygenator is a cardiopulmonary bypass blood oxygenator with an integral heat exchanger.

This document describes the Performa Adult Hollow Fiber Membrane Oxygenator, a medical device, and its evaluation for substantial equivalence to a predicate device. The information provided outlines the non-clinical and in vitro testing conducted. It is important to note that this document is a 510(k) summary, which typically focuses on demonstrating equivalence to an already approved device rather than a comprehensive de novo submission requiring extensive proof of safety and effectiveness from scratch.

Here's an analysis of the provided text in the context of acceptance criteria and a study:

1. A table of acceptance criteria and the reported device performance

The document does not provide a specific table of acceptance criteria with numerical targets. Instead, it states that the tests "met established specifications." The "established specifications" likely refer to the requirements outlined in ISO 7199 and the FDA Guidance for Cardiopulmonary Bypass Oxygenators.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

• Sample Size: The document does not explicitly state the sample size (number of devices) used for the non-clinical and in vitro tests. It refers to "Applicable tests" and "The Performa Oxygenator aged to 3 years was tested," implying that a certain number of devices underwent these evaluations. Without specific numbers, it's impossible to quantify the sample size.
• Data Provenance: The tests seem to have been conducted by Dideco S.r.l., which is based in Mirandola (MO), Italy. The data is in vitro and non-clinical, meaning it's from laboratory testing rather than human subjects. It is prospective testing, as the device was manufactured and then subjected to these tests to assess its performance.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This section is not applicable to the provided document. The study described is an in vitro and non-clinical engineering and performance evaluation of a device. It does not involve human subjects, expert review of images, or clinical outcomes that would require "ground truth" established by medical experts in the way that, for example, an AI diagnostic device would. The "ground truth" here is the established scientific and engineering principles and the specifications outlined in ISO and FDA guidance documents.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This section is not applicable. Adjudication methods like 2+1 or 3+1 are used in clinical trials or studies where there are subjective interpretations of data (e.g., medical images, patient symptoms) that require consensus among multiple experts. The tests described are objective, measurable physical and chemical properties of the device, assessed against predefined quantitative specifications.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This section is not applicable. An MRMC study is relevant for diagnostic or screening devices where human readers (e.g., radiologists) interpret cases (e.g., medical images) with and without the assistance of an AI algorithm. The Performa Adult Hollow Fiber Membrane Oxygenator is a therapeutic device (for cardiopulmonary bypass), not a diagnostic tool, and its evaluation does not involve human readers interpreting cases or AI assistance in that context.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This section is not applicable. "Standalone performance" in this context typically refers to the performance of an AI algorithm independent of human intervention. The Performa device is a physical medical device, not an AI algorithm. Its performance is evaluated mechanically, chemically, and biologically through in vitro tests.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

As mentioned in point 3, the concept of "ground truth" for this type of device evaluation differs from clinical studies involving diagnostic accuracy. The "ground truth" or reference standards used are:

• Established specifications/standards: Primarily the requirements from ISO 10993-1:1997 (for biocompatibility) and ISO 7199 (for in vitro performance characteristics such as gas transfer, pressure drop, plasma leakage, heat exchange, hemolysis, operating blood volume, and mechanical integrity).
• FDA Guidance: The FDA May 1, 1995 Memorandum (for biocompatibility) and the Guidance for Cardiopulmonary Bypass Oxygenators 510(k) submissions -- Final Guidance for industry and FDA Staff November 13, 2000 provided the framework and specific criteria for the in vitro testing.

These standards serve as the objective "ground truth" against which the device's performance is measured.

8. The sample size for the training set

This section is not applicable. A "training set" refers to data used to train a machine learning or AI model. The Performa oxygenator is a physical medical device, not an AI algorithm, and therefore does not have a "training set."

9. How the ground truth for the training set was established

This section is not applicable. As there is no training set for an AI algorithm, the concept of establishing ground truth for it does not apply here.

Ask a specific question about this device

The Dideco D 905 EOS Hollow Fiber Oxygenator with Integrated Hardshell Venous/Cardiotomy Reservoir is intended for use in patients who undergo cardiopulmonary bypass surgery requiring extracorporeal circulation with a maximum blood flow rate of 5 liters /minute. It provides oxygenation and carbon dioxide removal from venous blood. The integrated heat exchanger provides blood temperature control and allows the use of hypothermia or aids in the maintenance of normothermia during surgery. The venous reservoir with cardiotomy filter is intended to collect blood aspirated from the operating field during surgical procedures and the blood from patient's veins (gravity or vacuum assisted) during normal operation to assure the proper oxygenation capability of the device. The device is intended to be used for 6 hours or less.

The D 905 EOS Hollow Fiber Oxygenator With Integrated Hardshell Venous/Cardiotomy Reservoir (hereafter referred to as the D 905 EOS) is a high efficiency microporous hollow fiber membrane oxygenator integrated with an heat exchanger and connected to an hardshell venous/cardiotomy reservoir. The device is a modified version of the currently marketed D 903 Avant 2 Ph.I.S.I.O (K033323) predicate device (hereafter referred to as the Avant Ph.1.S.I.O.). The modification is limited to an overall reduction in the size of the device. The reduction in size enables the device to be better suited for the pediatric and small adult patient population.

Here's an analysis of the provided text regarding the D 905 EOS Oxygenator, extracting information relevant to acceptance criteria and the study proving it meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly list quantitative acceptance criteria in a dedicated table. Instead, it states that the test results "met established specifications" and that the device is "substantially equivalent" to predicate devices. The performance is reported in relation to these comparisons.

2. Sample Size Used for the Test Set and Data Provenance

The document does not specify a distinct "test set" sample size for each performance characteristic. Instead, it refers to in-vitro testing performed on the "D 905 EOS" (the device itself) and, "for comparative purposes," on the "D 903 Avant 2 Ph.I.S.I.O." and the "Cobe Optimin predicate device."

• Sample Size: Not explicitly stated as a number of devices or data points for the in-vitro tests. It refers to testing the device and predicate devices.
• Data Provenance: Retrospective for the predicate devices as they are "legally marketed." Prospective for the D 905 EOS, as the testing was conducted to support its 510(k) submission. There is no mention of country of origin for the data collection, but the submitter is Italian (Dideco S.r.l.).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This information is not provided in the document. The studies described are in-vitro tests, which typically rely on standardized laboratory measurements and comparison to objective specifications and predicate device performance, rather than expert judgment for "ground truth."

4. Adjudication Method for the Test Set

Not applicable. As described above, the studies are in-vitro tests with objective measurements, not studies requiring expert adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This device is a medical oxygenator, not an AI-based diagnostic or assistive technology that would involve "human readers" or "AI assistance" in the context of imaging or similar interpretation tasks.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

Not applicable. The device itself is a standalone medical device. The "standalone" concept typically applies to software or AI algorithms operating independently of human intervention. Here, the device's performance was evaluated in various standalone in-vitro tests.

7. The Type of Ground Truth Used

The "ground truth" for the in-vitro performance characteristics was established by:

• Established Specifications: These would be pre-defined numerical or qualitative criteria based on regulatory guidelines, engineering principles, and clinical requirements for oxygenators.
• Predicate Device Performance: The functional parameters of the D 903 Avant 2 Ph.I.S.I.O. and Cobe Optimin served as benchmarks for demonstrating substantial equivalence.

There is no mention of pathology, outcomes data, or expert consensus (in the context of clinical interpretation) as ground truth.

8. The Sample Size for the Training Set

Not applicable. This device is a physical medical device, not a software algorithm that would require a "training set" in the context of machine learning. The term "training set" refers to data used to train an AI model.

9. How the Ground Truth for the Training Set Was Established

Not applicable, for the same reasons as point 8.

Ask a specific question about this device

Ask a specific question about this device